Terns Pharmaceuticals announced that new preclinical data from a transgenic mouse model evaluating TERN-601, the Company’s novel oral GLP-1R agonist, were highlighted in a poster presentation at the American Diabetes Association’s 83rd Annual Scientific Sessions, which took place from June 23-26, 2023 in San Diego. “We are excited by these new preclinical data shared at ADA, which demonstrate the ability of TERN-601 to significantly improve glucose tolerance, suppress food intake and slow gastric emptying in transgenic mice,” said Sen Sundaram, chief executive officer at Terns. “These data are very encouraging and support our plans to initiate a Phase 1 first-in-human clinical trial in subjects with an elevated body mass index in the second half of this year, with top-line data expected in 2024.”…In addition, Terns announces that management will participate in a Fireside Chat at the Piper Sandler Inaugural Obesity Investor Day and will host a webinar to review Terns’ obesity franchise, including the TERN-601 program and additional development efforts underway in obesity.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TERN:
- Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
- Terns Pharmaceuticals initiated with a Buy at Mizuho
- Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
- Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting